Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Evolving Treatment Strategies for Chronic Lymphocytic Leukemia: Insights From Experts Across Mayo Clinic Locations : Episode 2

Navigating 1L Treatment Selection with BTKis in CLL

January 11, 2024
By Sameer A. Parikh, MD
Sikander Ailawadhi, MD
  • Mazie Tsang, MD, MAS, MS
  • Amber Koehler, PA-C, MS

Opinion
Video

Expert faculty discuss consideration factors in guiding frontline treatment selection with BTKis in CLL.

Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time -0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions and subtitles off, selected

      This is a modal window.

      Beginning of dialog window. Escape will cancel and close the window.

      Text
      Background
      Window
      Font Size
      Text Edge Style
      Font Family

      End of dialog window.

      EP: 1.Evolving Front-line Treatment Options for CLL

      Now Viewing

      EP: 2.Navigating 1L Treatment Selection with BTKis in CLL

      EP: 3.Updates on BTKi Monotherapy for CLL in the Frontline Setting

      EP: 4.The Role of BTKi + Obinutuzumab for 1L Treatment of CLL

      EP: 5.Expert Perspectives on Fixed Duration Therapy with Venetoclax + Obinutuzumab

      EP: 6.Updates on Combination Treatment Approaches with BTKi + Venetoclax

      EP: 7.Navigating Treatment Selection for CLL in the Relapsed/Refractory Setting

      EP: 8.Expert Insights on Extended Follow-Up Data from ALPINE and ELEVATE-RR

      EP: 9.Consideration Factors in Treatment Selection for BTKi Therapy in R/R CLL

      EP: 10.Key Considerations in Managing Hypertension Risk with BTKis in CLL

      EP: 11.Expert Perspectives on Managing Risk of Atrial Fibrillation with BTKis in CLL

      EP: 12.Managing Bleeding Risk in Patients with CLL on BTKi Therapy

      EP: 13.Utilizing Real-World Data for Informed Decision-Making in CLL

      EP: 14.Navigating Treatment Resistance and Sequencing in CLL

      EP: 15.Advancements with Novel Treatment Approaches in CLL

      EP: 16.Future Perspectives and Unmet Needs in CLL

      Recent Videos
      Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
      Novel BTK Degrader Shows Activity in CLL/SLL Regardless of Mutation Status
      More Research Needed to Ascertain Ziftomenib’s Mechanism of Action in AML
      More Research Needed to Ascertain Ziftomenib’s Mechanism of Action in AML
      More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
      Bexmarilimab Shows Survival Efficacy in Relapsed/Refractory MDS
      Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
      CLL Workshop Emphasizes Engaging Conversations on Shared Treatment Planning
      Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
      Navigating Treatment Decision-Making Challenges in CLL Management
      Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
      Asciminib Appears to Benefit All Chronic Myeloid Leukemia Subgroups
      Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
      Undetected MRD Confers Improved PFS With Ibrutinib Combo in CLL/SLL
      Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
      Spreading Greater CAR T-Cell Therapy Education in the Community Setting
      Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
      Avoiding CAR T-Cell Collection Problems Following Bridging Therapies
      Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
      Academic/Community Collaboration May Help Facilitate CAR T Therapy Access
      Related Content
      Advertisement

      FDA Accepts sNDA for Decitabine/Cedazuridine Combo in Newly Diagnosed AML

      FDA Accepts sNDA for Decitabine/Cedazuridine Combo in Newly Diagnosed AML

      Ariana Pelosci
      July 10th 2025
      Article

      A PDUFA date for decitabine/cedazuridine and venetoclax in newly diagnosed AML has been set for February 25, 2026.


      An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

      CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

      Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
      June 9th 2025
      Podcast

      An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


      The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.

      SGR-1505 Earns Fast Track Designation for R/R Waldenström Macroglobulinemia

      Roman Fabbricatore
      July 1st 2025
      Article

      The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.


      Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

      Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

      Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
      May 5th 2025
      Podcast

      Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.


      Post-transplant Cyclophosphamide as GVHD Prophylaxis in Patients Receiving Mismatched Unrelated HCT: The PHYLOS Trial

      Post-transplant Cyclophosphamide as GVHD Prophylaxis in Patients Receiving Mismatched Unrelated HCT: The PHYLOS Trial

      American Society for Transplantation and Cellular Therapy
      June 25th 2025
      Article

      Among 77 enrolled patients, the cumulative incidence of grades 2 to 4 aGVHD at day 100 post-transplantation was 18.2% (95% CI, 10.6–27.6%).


      The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

      FDA Grants Priority Review to Revumenib in R/R NPM1-Mutant AML

      Russ Conroy
      June 25th 2025
      Article

      The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

      Related Content
      Leukemia
      |
      Hematologic Oncology
      |
      Evolving Treatment Strategies for Chronic Lymphocytic Leukemia: Insights From Experts Across Mayo Clinic Locations
      Advertisement

      FDA Accepts sNDA for Decitabine/Cedazuridine Combo in Newly Diagnosed AML

      FDA Accepts sNDA for Decitabine/Cedazuridine Combo in Newly Diagnosed AML

      Ariana Pelosci
      July 10th 2025
      Article

      A PDUFA date for decitabine/cedazuridine and venetoclax in newly diagnosed AML has been set for February 25, 2026.


      An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

      CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

      Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
      June 9th 2025
      Podcast

      An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


      The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.

      SGR-1505 Earns Fast Track Designation for R/R Waldenström Macroglobulinemia

      Roman Fabbricatore
      July 1st 2025
      Article

      The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.


      Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

      Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

      Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
      May 5th 2025
      Podcast

      Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.


      Post-transplant Cyclophosphamide as GVHD Prophylaxis in Patients Receiving Mismatched Unrelated HCT: The PHYLOS Trial

      Post-transplant Cyclophosphamide as GVHD Prophylaxis in Patients Receiving Mismatched Unrelated HCT: The PHYLOS Trial

      American Society for Transplantation and Cellular Therapy
      June 25th 2025
      Article

      Among 77 enrolled patients, the cumulative incidence of grades 2 to 4 aGVHD at day 100 post-transplantation was 18.2% (95% CI, 10.6–27.6%).


      The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

      FDA Grants Priority Review to Revumenib in R/R NPM1-Mutant AML

      Russ Conroy
      June 25th 2025
      Article

      The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

      Advertisement
      Advertisement
      Advertisement
      Advertisement
      x
      About
      Advertise
      CureToday.com
      OncLive.com
      OncNursingNews.com
      TargetedOnc.com
      Editorial
      Contact
      Terms and Conditions
      Privacy
      Do Not Sell My Personal Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.